logo
  Join        Login             Stock Quote

Predictive Biosciences to Present at AACR Annual Meeting and Oak Ridge Conference

Friday, April 5, 2013 7:00 AM


Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced the company will present data at two key scientific conferences this month on the latest in bladder cancer advancements using next-generation sequencing for multiple biomarker detection.

Predictive Biosciences will present two talks at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 6 – 10, 2013 in Washington, DC. The first presentation entitled, “Next-Gen deep amplicon sequencing of TP53 complements FGFR3 for the detection of bladder cancer-related mutations” will be given by Anthony P. Shuber, chief technology officer. The second presentation entitled, “Detection of bladder cancer-associated gene methylation using next-gen bisulfite sequencing” will be given by Cecilia Fernandez, director of research. Both presentations will take place on Sunday, April 7, 2013, from 1:00 p.m. - 5:00 p.m.

The company will also present at the 45th Annual Oak Ridge Conference, “Emerging Technologies for 21st Century Diagnostics” to be held April 18 – 19, 2013 in Baltimore, MD. Anthony P. Shuber will present on Friday, April 19, 3:10 – 3:25 p.m. EST in a session entitled “Biomarkers: Buyer Beware”. His talk will discuss the updates made to the company’s next-generation sequencing assay for bladder cancer, which includes the ability to analyze protein and DNA simultaneously on a next-generation sequencing platform.

“As the first company to introduce molecular diagnostic tests into routine clinical use using next-generation sequencing, we continue to leverage our proprietary technology based on the simultaneous detection of DNA and protein biomarkers. In addition to what we are presenting at these key scientific conferences, we are developing additional molecular tests applying our novel approaches to other cancers such as prostate cancer,” said Anthony P. Shuber.

About Predictive Biosciences

Predictive Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. Predictive Biosciences’ new approach to molecular testing analyzes multiple biomarkers (DNA and protein) together in a single test to determine disease state. The company’s CertNDx™ tests enable physicians to accurately detect cancer. Headquartered in Lexington, MA, the company is backed by leading investors, including Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, New Enterprises Associates, Inc. (NEA) and ProQuest Investments. For additional information, please visit www.predictivebiosci.com.

(Source: Business Wire )
(Source: Quotemedia)

Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.